Skip to main content
ConductScienceScienceDex
zenodorestricted

Gender and age normalization and ventilation efficiency during exercise in heart failure with reduced ejection fraction.

<p>Raw data of the manuscript &quot;Gender and age normalization and ventilation efficiency during exercise in heart failure with reduced ejection fraction.&quot;</p> <p>&nbsp;</p> <p><strong>Aims:&nbsp;</strong>Ventilation vs. carbon dioxide production (VE/VCO<sub>2</sub>&nbsp;) is among the strongest cardiopulmonary exercise testing prognostic parameters in heart failure (HF). It is usually reported as an absolute value. The current definition of normal VE/VCO<sub>2</sub>&nbsp;slope values is inadequate, since it was built from small groups of subjects with a particularly limited number of women and elderly. We aimed to define VE/VCO<sub>2</sub>&nbsp;slope prediction formulas in a sizable population and to test whether the prognostic power of VE/VCO<sub>2</sub>&nbsp;slope in HF was different if expressed as a percentage of the predicted value or as an absolute value.</p> <p><strong>Methods and results:&nbsp;</strong>We calculated the linear regressions between age and VE/VCO<sub>2</sub>&nbsp;slope in 1136 healthy subjects (68% male, age 44.9 &plusmn; 14.5, range 13-83 years). We then applied age-adjusted and sex-adjusted formulas to predict VE/VCO<sub>2</sub>&nbsp;slope to HF patients included in the metabolic exercise test data combined with cardiac and kidney indexes score database, which counts 6112 patients (82% male, age 61.4 &plusmn; 12.8, left ventricular ejection fraction 33.2 &plusmn; 10.5%, peakVO<sub>2</sub>&nbsp;14.8 &plusmn; 4.9, mL/min/kg, VE/VCO<sub>2</sub>&nbsp;slope 32.7 &plusmn; 7.7) from 24 HF centres. Finally, we evaluated whether the use of absolute values vs. percentages of predicted VE/VCO<sub>2</sub>&nbsp;affected HF prognosis prediction (composite of cardiovascular mortality + urgent transplant or left ventricular assist device). We did so in the entire cardiac and kidney indexes score population and separately in HF patients with severe (peakVO<sub>2</sub>&nbsp;&lt; 14 mL/min/kg, n = 2919, 61.1 events/1000 pts/year) or moderate (peakVO<sub>2</sub>&nbsp;&ge; 14 mL/min/kg, n = 3183, 19.9 events/1000 pts/year) HF. In the healthy population, we obtained the following equations: female, VE/VCO<sub>2</sub>&nbsp;= 0.052 &times; Age + 23.808 (r = 0.192); male, VE/VCO<sub>2</sub>&nbsp;= 0.095 &times; Age + 20.227 (r = 0.371) (P = 0.007). We applied these formulas to calculate the percentages of predicted VE/VCO<sub>2</sub>&nbsp;values. The 2-year survival prognostic power of VE/VCO<sub>2</sub>&nbsp;slope was strong, and it was similar if expressed as absolute value or as a percentage of predicted value (AUCs 0.686 and 0.690, respectively). In contrast, in severe HF patients, AUCs significantly differed between absolute values (0.637) and percentages of predicted values (0.650, P = 0.0026). Moreover, VE/VCO<sub>2</sub>&nbsp;slope expressed as a percentage of predicted value allowed to reclassify 6.6% of peakVO<sub>2</sub>&nbsp;&lt; 14 mL/min/kg patients (net reclassification improvement = 0.066, P = 0.0015).</p> <p><strong>Conclusions:&nbsp;</strong>The percentage of predicted VE/VCO<sub>2</sub>&nbsp;slope value strengthens the prognostic power of VE/VCO<sub>2</sub>&nbsp;in severe HF patients, and it should be preferred over the absolute value for HF prognostication. Furthermore, the widespread use of VE/VCO<sub>2</sub>&nbsp;slope expressed as percentage of predicted value can improve our ability to identify HF patients at high risk, which is a goal of utmost clinical relevance.</p>

ShareScore

8/100

Overall dataset sharing score

Score breakdown

These five areas show where the dataset supports — or may limit — practical reuse.

Stewardship
4
Harmonization
4
Access
0
Reuse readiness
0
Engagement
0

Dataset details

Repository
zenodo
Published
December 14, 2020
License
Not reported
DOI
10.5281/zenodo.4322953

Scored with release 0.9.0

ScienceDex for faculty

Your academic CV and NIH biosketch

Make your CV in your school's format and your NIH biosketch from it, then download both as Word files.